GlassScriptPhysician profile
Ericka S Sikkenga
NPI 1952520736
$11,892.79
in general payments reported to CMS, 2019-2025
26 companies · $315 in 2025
The $315 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,743 · 2020: $179 · 2021: $2,767 · 2022: $1,739 · 2023: $2,377 · 2024: $773 · 2025: $315.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,919 · Travel and Lodging: $1,454 · Education: $90.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,919.48 |
| Travel and Lodging | $1,453.80 |
| Education | $90.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,488.70 | 2019-2025 | Da Vinci Surgical System |
| Abbvie INC. | $4,380.74 | 2019-2023 | Lo Loestrin Fe, Orilissa, Liletta |
| Astellas Pharma US INC | $491.43 | 2023-2025 | Veozah |
| Hologic Sales and Service, LLC | $385.78 | 2019-2024 | Acessa Provu System, Novasure, Fluent Fluid Management System |
| Aspira Women'S Health INC | $288.91 | 2021-2025 | Ova1 |
| Sumitomo Pharma America, INC. | $257.93 | 2023-2025 | Myfembree, Gemtesa |
| Ethicon US, LLC | $219.50 | 2019-2020 | |
| Lupin INC. | $212.84 | 2019-2020 | |
| Minerva Surgical, INC | $151.78 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $141.61 | 2019-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $129.78 | 2022 | |
| Pfizer INC. | $126.74 | 2023-2024 | |
| Organon LLC | $126.43 | 2023-2025 | Nexplanon, Nuvaring |
| Daiichi Sankyo INC. | $110.06 | 2019-2024 | Injectafer |
| Merck Sharp & Dohme LLC | $60.52 | 2020-2025 | Gardasil 9, Gardasil |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $56.16 | 2023 | Saffron |
| Amag Pharmaceuticals, INC. | $35.49 | 2019 | |
| Allergan, INC. | $33.97 | 2019-2020 | |
| Exeltis, USA INC. | $32.68 | 2022-2023 | Slynd |
| Sage Therapeutics, LLC | $32.60 | 2020 | |
| Meditrina | $31.31 | 2023-2025 | |
| Biogen, INC. | $28.49 | 2024 | Zurzuvae |
| Myovant Sciences INC. | $19.45 | 2021 | |
| Alexion Pharmaceuticals, INC. | $17.46 | 2019 | |
| Novo Nordisk INC | $16.82 | 2022 | |
| Smith+Nephew, INC. | $15.61 | 2025 | Pico 7 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ericka Sikkenga listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.